Abstract |
Even with novel chemotherapeutic agents and external beam radiation therapy, the prognosis of neoplastic meningitis secondary to malignant melanoma is still dismal. The authors report a case study of a 46-year-old white female who presented with progressive hearing loss, severe headaches, nausea, vomiting, and a rapid decline in neurologic status. She was referred to Duke University Medical Center after conventional chemotherapy for malignant melanoma failed. She was enrolled in a Phase I trial of (131)I-labeled monoclonal antibody Mel-14 F(ab')(2) fragment administered intrathecally. Within a year after her treatment, she recovered, having a normal neurologic exam except for residual bilateral hearing loss. The authors discuss dosimetry, preclinical, and clinical studies conducted with Mel-14 F(ab')(2) and introduce a potentially promising therapy option in the treatment of neoplastic meningitis in patients with malignant melanoma. Currently, the patient remains neurologically normal except for a mild bilateral hearing loss more than 4 years after treatment and has no radiographic evidence of neoplastic meningitis.
|
Authors | I Cokgor, G Akabani, H S Friedman, A H Friedman, M R Zalutsky, L M Zehngebot, J M Provenzale, C D Guy, C J Wikstrand, D D Bigner |
Journal | Cancer
(Cancer)
Vol. 91
Issue 9
Pg. 1809-13
(May 01 2001)
ISSN: 0008-543X [Print] United States |
PMID | 11335907
(Publication Type: Case Reports, Journal Article, Research Support, U.S. Gov't, P.H.S.)
|
Copyright | Copyright 2001 American Cancer Society. |
Chemical References |
- Antibodies, Monoclonal
- Iodine Radioisotopes
- Radiopharmaceuticals
- L-Selectin
- Chondroitin Sulfates
|
Topics |
- Antibodies, Monoclonal
(adverse effects, therapeutic use)
- Chondroitin Sulfates
(immunology)
- Female
- Humans
- Iodine Radioisotopes
(adverse effects, therapeutic use)
- L-Selectin
(immunology)
- Melanoma
(radiotherapy)
- Meningitis
(etiology)
- Middle Aged
- Radiopharmaceuticals
(adverse effects, therapeutic use)
|